Modern views on immunological biomarkers of colon cancer
Автор: Tryakin A.A., Khakimova G.G., Zabotina T.N., Borunova A.A., Malikhova O.A.
Журнал: Злокачественные опухоли @malignanttumors
Статья в выпуске: 4 т.8, 2018 года.
Бесплатный доступ
The article briefly describes the mechanism of action of immunotherapeutic drugs that suppress the activity of “checkpoints” of the immune response CTLA-4 and PD-1. Modern methods of clinical efficacy and advantages of applying nivolumab, pembrolizumab and atezolizumab in colorectal cancer. The existing evidence base of the potential predictive and prognostic role of MSI status is summarized and presented information on the prospects for the further development of this therapeutical treatment of malignant tumors.
Ctla-4, pd-1, pd-l1, сhemotherapy, immunotherapy, checkpoint, nivolumab, pembrolizumab, atezolizumab, biomarkers, efficacy
Короткий адрес: https://sciup.org/140243807
IDR: 140243807 | DOI: 10.18027/2224-5057-2018-8-4-50-58
